US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Inclusion Criteria: * clinical diagnosis of advanced upper lobe predominant emphysema * age \>/= 40 years * clinically significant dyspnea * failure of standard medical therapy to relieve symptoms (inhaled beta agonist and inhaled anticholinergic) * pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 \< 45% predicted and experiencing \< 30% or 300 mL improvement using bronchodilator; TLC \> 110% predicted; RV \> 150% predicted) * 6 Minute Walk Distance \>/= 150 m Exclusion Criteria: * alpha-1 protease inhibitor deficiency * homogeneous disease * tobacco use within 4 months of initial visit * body mass index \< 15 kg/m2 or \> 35 kg/m2 * clinically significant asthma, chronic bronchitis or bronchiectasis * allergy or sensitivity to procedural components * pregnant, lactating or unwilling to use birth control if required * prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endobronchial valve placement, airway stent placement or pleurodesis * comorbid condition that could adversely influence outcomes * inability to tolerate bronchoscopy under conscious sedation (or anesthesia)